Company Profile
Karyopharm Therapeutics Stock Price, News & Analysis
- Ticker:
- KPTI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.95 USD (+2.09%)
Close
Last updated: August 6, 2026
209M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KPTI closed up 2.09% at $1.95. No new same-company headline was identified in the current news window.
Company overview
Nuclear Export Oncology Company
Karyopharm Therapeutics is a commercial-stage oncology company built around inhibition of exportin 1, a nuclear export protein involved in cancer-cell survival.
XPOVIO Franchise
XPOVIO, or selinexor, is commercialized in hematologic malignancies and provides the commercial base for development in additional cancers.
Selinexor Mechanism
Selinexor inhibits exportin 1 to retain tumor-suppressor proteins inside the nucleus, creating a common biological strategy across hematologic and solid tumors.
Myelofibrosis Programs
The Phase 3 SENTRY study evaluates once-weekly selinexor with ruxolitinib in JAK inhibitor-naïve myelofibrosis. SENTRY-2 evaluates selinexor in patients previously treated with JAK inhibitors.
Endometrial Cancer and Multiple Myeloma
Karyopharm is also studying maintenance selinexor in advanced or recurrent endometrial cancer and in the Phase 3 XPORT-MM-031 study in multiple myeloma.
Future catalysts
Topline data from the Phase 3 XPORT-EC-042 endometrial cancer trial are expected in mid-2026.
Additional topline data from the 60 mg cohort of the Phase 2 SENTRY-2 myelofibrosis trial are expected in the second half of 2026.
Topline data from the event-driven Phase 3 XPORT-MM-031 trial are expected in the second half of 2026.
Recent news
- 01
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Karyopharm Therapeutics
- 02
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Source: Karyopharm Therapeutics
- 03
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
Source: Karyopharm Therapeutics
- 04
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Karyopharm Therapeutics
- 05
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Source: Karyopharm Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Karyopharm Therapeutics (KPTI)?
Karyopharm Therapeutics (KPTI) most recently closed at 1.95 USD, a +2.09% move versus the previous session.
What is the market cap of Karyopharm Therapeutics (KPTI)?
Karyopharm Therapeutics currently has a market capitalization of 209M USD on BioPharmSignal.
What does Karyopharm Therapeutics do?
Nuclear Export Oncology Company Karyopharm Therapeutics is a commercial-stage oncology company built around inhibition of exportin 1, a nuclear export protein involved in cancer-cell survival. XPOVIO Franchise XPOVIO, or selinexor, is commercialized in hematologic malignancies and provides the commercial base for development in additional cancers. Selinexor...
On which exchange is KPTI stock listed?
Karyopharm Therapeutics (KPTI) is associated with NASDAQ, United States, Biopharma.
What is SENTRY-2?
Additional topline data from the 60 mg cohort of the Phase 2 SENTRY-2 myelofibrosis trial are expected in the second half of 2026.
Which conditions is Karyopharm Therapeutics targeting with SENTRY-2?
Karyopharm Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Karyopharm Therapeutics describe recent progress with SENTRY-2?
Additional topline data from the 60 mg cohort of the Phase 2 SENTRY-2 myelofibrosis trial are expected in the second half of 2026.
What is XPORT-MM-031?
Endometrial Cancer and Multiple Myeloma Karyopharm is also studying maintenance selinexor in advanced or recurrent endometrial cancer and in the Phase 3 XPORT-MM-031 study in multiple myeloma.